Using genetic markers to understand pancreatic and liver cancer origins
Official title: Genomic lineage traces as biomarkers for human pancreatic and liver cancer
Funded at University of Utah · NIH-11030318 · Data updated 2026-11-12
This study is looking at how the genes of pancreatic and liver cancer cells can help us understand where the cancer started and how it behaves, so we can better match treatments to patients and improve their care.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | February 6, 2024 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $179,988 |
| NIH project number | 5R21CA288671-02 |
| Project ID | NIH-11030318 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma or hepatocellular carcinoma.
✕Less likely to help
Patients with other types of cancer or those without a confirmed diagnosis of pancreatic or liver cancer may not benefit from this research.
What this research studies
This research investigates how the origin of cancer cells in pancreatic and liver cancers can be traced through specific genetic markers. By analyzing these markers, researchers aim to understand how different subtypes of these cancers develop and how they relate to patient outcomes. The study utilizes advanced techniques to identify these lineage traces, which could help in classifying tumors and tailoring treatments for patients. The ultimate goal is to improve patient stratification based on the genetic characteristics of their tumors.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment strategies for patients with pancreatic and liver cancers.
How similar studies have gone: Previous studies have shown promise in using genetic markers to understand cancer origins, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Murtaugh, Lewis C — University of Utah
- Study coordinator: Murtaugh, Lewis C
Related research
Other NIH-funded projects on the same topics.
-
AI-powered liver cancer screening using ultrasound blood flow patterns
A new AI-based method analyzes liver blood flow signals to help detect liver cancer early in people with liver disease, especially in settings with limited resources.
-
Aging and liver cancer: new ways to prevent and fight hepatocellular carcinoma
This research explores how aging promotes liver cancer and tests new preventive approaches that could help people at higher risk due to age.
-
Testing new therapies for pediatric and young adult sarcoma, kidney, and liver cancers
Researchers are testing new drugs and smart combinations in models of pediatric cancers to help guide future treatments for kids and young adults.
-
Liver cancer prevention and care in Uganda using HIV clinic networks
A program in Uganda uses existing HIV care systems to roll out liver cancer prevention, screening, and treatment strategies tailored to local needs.
-
Leveraging HIV care to prevent liver cancer in Uganda
A program in Uganda uses existing HIV care clinics to roll out a liver cancer prevention and treatment plan tailored to local needs.
-
Damaged telomeres and telomerase in liver scarring and liver cancer
Using human stem-cell models, researchers look at how short telomeres and telomerase changes can lead to liver scarring and liver cancer for people with telomere-related risks.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.